Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction and Receiving Spironolactone

NCT04676646 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04676646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction and Receiving Spironolactone
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
March 8, 2021
Completion date
July 15, 2024
Enrollment
366 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with reduced ejection fraction, hyperkalaemia